Al­lakos drops a pair of duds on pa­tient-re­port­ed symp­tom re­lief for GI dis­ease, va­por­iz­ing bil­lions off its val­ue

Tar­get­ing over­ac­tive white blood cells known as eosinophils has be­come a hot drug tar­get with mul­ti­ple ap­provals in re­cent years. One com­pa­ny with big plat­form hopes tar­get­ing those cells has now blown up in spec­tac­u­lar fash­ion af­ter a lead drug showed lit­tle symp­tom re­lief for pa­tients.

In two sep­a­rate Phase II/III stud­ies across mul­ti­ple types of eosinophilic gas­troin­testi­nal dis­ease, Al­lakos’ lirente­limab showed a sig­nif­i­cant re­duc­tion in eosinophil lev­els in the blood, but those re­sults didn’t car­ry over in­to al­le­vi­at­ing symp­toms. On co-pri­ma­ry end­points in both stud­ies of self-re­port­ed symp­tom re­lief, pa­tients didn’t see any sig­nif­i­cant im­prove­ment over place­bo.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN